Every FDA-Approved Weight Loss Medication in 2026: A Complete Guide

The landscape of FDA-approved weight loss medications has expanded significantly. As of mid-2026, patients and prescribers have more options than ever — ranging from daily pills to weekly injections, older generics to cutting-edge GLP-1 receptor agonists. This guide covers every FDA-approved option currently available, what the clinical data shows, and how they compare.

The GLP-1 and Dual-Agonist Era

Semaglutide (Wegovy / Wegovy HD / Wegovy Pill)

Semaglutide is the most widely prescribed weight loss medication in the United States. The injectable form (Wegovy) was approved in 2021 and produces average weight loss of approximately 15% of body weight over 68 weeks at the 2.4 mg dose. In March 2026, the FDA approved Wegovy HD, a higher 7.2 mg dose that delivers even greater weight reduction.

The Wegovy pill (oral semaglutide 25 mg) was approved in December 2025 — the first oral GLP-1 for weight management. In clinical trials, it achieved 13.6–16.6% weight loss over 64 weeks. The pill must be taken on an empty stomach with a 30-minute fasting window. Wegovy is also the only weight loss medication with an FDA-approved cardiovascular risk reduction indication, based on the SELECT trial.

Tirzepatide (Zepbound)

Zepbound is a dual GLP-1/GIP receptor agonist approved for obesity in late 2023. It is currently the most effective weight loss medication on the market. In the SURMOUNT-1 trial, participants lost an average of 22.5% of body weight at the highest dose over 72 weeks. Zepbound is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity — the first FDA-approved medication for that use.

Orforglipron (Foundayo)

Foundayo, approved April 1, 2026, is Eli Lilly's oral GLP-1 receptor agonist. Unlike the Wegovy pill, Foundayo is a small molecule that can be taken at any time of day with no food or water restrictions. In the ATTAIN-1 trial, the 36 mg dose produced average weight loss of 12.4% over 72 weeks. Foundayo starts at $149/month for the lowest dose.

Liraglutide (Saxenda)

Saxenda was the first GLP-1 approved for weight management in adults and is also approved for adolescents 12 and older. It requires daily injection and produces more modest weight loss — typically 5–8% of body weight. It remains relevant for patients who don't tolerate the newer agents or whose insurance covers it preferentially.

Older FDA-Approved Options

Phentermine-Topiramate (Qsymia)

Qsymia combines an appetite suppressant with an anticonvulsant in an extended-release capsule. Clinical trials showed about 10% weight loss at the highest dose. It's one of the more affordable options but carries risks including increased heart rate, birth defects (requires pregnancy prevention), and cognitive effects from topiramate.

Naltrexone-Bupropion (Contrave)

Contrave combines an opioid antagonist with an antidepressant. Weight loss averages about 5–6% of body weight. It may be a good fit for patients who also struggle with food cravings or have concurrent depression. It should not be used with opioid medications and can raise blood pressure.

Orlistat (Xenical / Alli)

Orlistat blocks fat absorption in the gut and produces modest weight loss of about 5% of body weight. It's available both by prescription (Xenical) and over-the-counter (Alli at a lower dose). GI side effects — oily stools, gas, and urgency — are common, especially with high-fat meals. It's the only weight loss medication available without a prescription.

Phentermine (Adipex-P / Lomaira)

Phentermine is one of the oldest and most affordable weight loss drugs. It's FDA-approved only for short-term use (typically less than 12 weeks), though some doctors prescribe it for longer periods. As a stimulant, it carries risks for patients with heart conditions or uncontrolled hypertension.

How They Compare